DNA (RECOMBINANT ADENO-ASSOCIATED VIRUS 2 VECTOR LYS-SAF302 HUMAN N-SULFOGLUCOSAMINE SULFOHYDROLASE CDNA-SPECIFYING)
Mucopolysaccharidosis Type IIIA
LYSOGENEgene_therapyPhase 2/3Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Mucopolysaccharidosis Type IIIA cohort.
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →